Kyverna Therapeutics

We are bringing curative living medicines to life to free patients from the siege of autoimmune disease.

[Kyverna Therapeutics @KyvernaT]

Today is #WorldLupusDay -

Be sure to read the article below from @biospace to learn more about how @KyvernaT is committed to improving treatment options for patients living with lupus by utilizing an anti-CD19 CAR-T cell therapy

https://t.co/P2K8uQFUZM

#lupus #LupusAwareness

[Kyverna Therapeutics @KyvernaT]

@KyvernaT is pleased to announce the successful closing of $85 million in our series B round of financing.

You can read the full press release here:

https://t.co/n0JUiGCNpc

#biotech #venturecapital #investors #cartcells

[Kyverna Therapeutics @KyvernaT]

@KyvernaT would like to congratulate our board member and @biowestlake’s co-founding managing director Dr. Beth Seidenberg on winning HBA’s Woman of the Year honor for 2022.

https://t.co/scSJIS1iok

#HBAimpact #genderequality #healthcare #HBAWOTY22

[Kyverna Therapeutics @KyvernaT]

Be sure to read @biospace's article on @KyvernaT's exclusive agreement to develop and later commercialize an allogeneic CD19 CAR-T cell therapy to treat a wide range of B cell-mediated autoimmune illnesses with @intelliatweets.

Find the article here:
https://t.co/9iO4V8cEvC

[Kyverna Therapeutics @KyvernaT]

@KyvernaT is pleased to announce a licensing and collaboration agreement with @intelliatweets for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases.

Read full release here:

https://t.co/xaIM081Gan

[Kyverna Therapeutics @KyvernaT]

Be sure to read @biospace's article for more information about @KyvernaT and our recent exclusive rights licensing deal to the IP of a novel clinical-stage anti-CD19 chimeric antigen receptor T-cell with @NIH.

Find the full article here:

https://t.co/7bEVcsiLQM

#TCELL #NIH

[Kyverna Therapeutics @KyvernaT]

@KyvernaT is pleased to announce we've entered into exclusive, worldwide licenses with @NIH for intellectual property related to a novel clinical-stage anti-CD19 CAR T-cell construct with properties uniquely suited for use in autoimmune diseases.

https://t.co/PBbHkbMOGK

[Kyverna Therapeutics @KyvernaT]

We are extremely excited to announce the appointment of Ian Clark as chair of the company's board of directors and the appointment of Karen Walker as Chief Technology Officer (CTO).

Follow the link to read the full release: https://t.co/Udbx1NhSSz

[Kyverna Therapeutics @KyvernaT]

We are pleased today to announce the appointment of James Chung, M.D., Ph.D., as the Company’s first Chief Medical Officer. Dr. Chung joins Kyverna from @amgen where he most recently was Executive Medical Director. For more: https://t.co/xBdfkteG8W #CMO #tamingautoimmunity